GIP and GLP-1 receptor co-agonist

Vk2735 sc

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

VK2735_SC

Mechanism: Dual incretin agonist (tirzepatide and others)
Trials: 1
Participants in these arms: 141

Doses in this pooled treatment

Effects across outcomes

Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.

Condition	Outcome	Window	Versus	Effect (95% CrI)	SUCRA
Overweight or obesity without diabetes (adults)	Serious adverse events	longest follow-up	Placebo	HR 1.77 (0.31 to 18.52)	0.42
Overweight or obesity without diabetes (adults)	Discontinuation due to adverse events	longest follow-up	Placebo	HR 11.44 (1.39 to 259)	0.15
Overweight or obesity without diabetes (adults)	Nausea	longest follow-up	Placebo	HR 2.51 (1.17 to 6.30)	0.62
Overweight or obesity without diabetes (adults)	Vomiting	longest follow-up	Placebo	HR 16.67 (2.33 to 334)	0.21
Overweight or obesity without diabetes (adults)	Diarrhea	longest follow-up	Placebo	HR 2.52 (0.79 to 10.83)	0.39
Overweight or obesity without diabetes (adults)	Constipation	longest follow-up	Placebo	HR 2.48 (0.85 to 8.94)	0.41
Overweight or obesity without diabetes (adults)	Gallbladder and biliary disease	longest follow-up	Placebo	HR 2.27 (0.13 to 80.58)	0.42

Trials

VENTURE
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 13-week Study of VK2735 for Weight Management in Subjects Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition
2023 · 176 randomized · 13 weeks